PACB Pacific Biosciences Of California Inc
Price (delayed)
$1.88
Market cap
$512.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$1.34B
Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a
Highlights
The quick ratio has soared by 120% YoY but it has contracted by 15% from the previous quarter
The revenue has increased by 29% YoY but it has decreased by 6% QoQ
PACB's net income is down by 35% QoQ and by 25% YoY
The EPS has contracted by 32% from the previous quarter and by 11% YoY
Key stats
What are the main financial stats of PACB
Market
Valuations
Earnings
Shares outstanding
272.53M
Market cap
$512.35M
Enterprise value
$1.34B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.04
Price to sales (P/S)
2.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.08
Revenue
$188.87M
EBIT
-$397.53M
EBITDA
-$354.08M
Free cash flow
-$260.9M
Per share
Balance sheet
Liquidity
EPS
-$1.5
Free cash flow per share
-$0.96
Book value per share
$1.81
Revenue per share
$0.69
TBVPS
$2.56
Total assets
$1.51B
Total liabilities
$1.02B
Debt
$924.95M
Equity
$492.7M
Working capital
$549.75M
Debt to equity
1.88
Current ratio
8.01
Quick ratio
6.92
Net debt/EBITDA
-2.33
Margins
Efficiency
Dividend
EBITDA margin
-187.5%
Gross margin
23.7%
Net margin
-212%
Operating margin
-225.8%
Return on assets
-23.5%
Return on equity
-61.4%
Return on invested capital
-27.4%
Return on capital employed
-27.8%
Return on sales
-210.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PACB stock price
How has the Pacific Biosciences Of California stock price performed over time
Intraday
0.53%
1 week
11.9%
1 month
20.51%
1 year
-80.58%
YTD
-80.84%
QTD
37.23%
Financial performance
How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$188.87M
Gross profit
$44.69M
Operating income
-$426.49M
Net income
-$400.38M
Gross margin
23.7%
Net margin
-212%
The net margin is down by 43% since the previous quarter but it is up by 2.9% year-on-year
PACB's operating margin is down by 41% since the previous quarter and by 9% year-on-year
The company's operating income fell by 41% YoY and by 33% QoQ
PACB's net income is down by 35% QoQ and by 25% YoY
Growth
What is Pacific Biosciences Of California's growth rate over time
Valuation
What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
1.04
P/S
2.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.08
The EPS has contracted by 32% from the previous quarter and by 11% YoY
The P/B is 88% below the 5-year quarterly average of 8.3 and 53% below the last 4 quarters average of 2.2
The company's equity fell by 24% QoQ and by 23% YoY
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 21.8 and 66% lower than the last 4 quarters average of 8.0
The revenue has increased by 29% YoY but it has decreased by 6% QoQ
Efficiency
How efficient is Pacific Biosciences Of California business performance
The ROS has contracted by 43% from the previous quarter
PACB's ROA is down by 42% from the previous quarter and by 35% YoY
The ROE has contracted by 42% from the previous quarter and by 21% YoY
The company's return on invested capital fell by 36% QoQ and by 29% YoY
Dividends
What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PACB.
Financial health
How did Pacific Biosciences Of California financials performed over time
The company's total assets is 48% higher than its total liabilities
The company's current ratio has surged by 132% YoY but it fell by 14% QoQ
The quick ratio has soared by 120% YoY but it has contracted by 15% from the previous quarter
The debt is 88% greater than the equity
The company's debt to equity rose by 31% QoQ and by 29% YoY
The company's equity fell by 24% QoQ and by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.